Despite intensive molecular biology investigations over the past 10 years, and an important breakthrough on how PML ± RARa, the fusion protein resulting from t(15;17), can alter RARa and PML functions, no de®nitive views on how leukemia is generated and by what mechanism(s) the normal phenotype is restored, are yet available.`Resistances' to pharmacological levels of all-trans-retinoic acid (ATRA) have been observed in experimental in vivo and in vitro models. In this review, we emphasize the key role played by signal cross-talk for both normal and neoplastic hemopoiesis. After an overview of reported experimental data on APL-cell maturation and apoptosis, we apply our current knowledge on signaling pathways to underline those which might generate signal cross-talks. The design of biological models suitable to decipher the integration of signal cross-talks at the transcriptional level should be our ®rst priority today, to generate some realistic therapeutic approaches After`Ten Years of Molecular APL', we still know very little about how the disease develops and how eective medicines work. Oncogene (2001) 20, 7161 ± 7177.
Twenty years of intense research eorts have been devoted to acute promyelocytic leukemia (APL) biology and maturation therapy of leukemias (reviewed in Melnick and Licht, 1999) : 10 years before the t(15;17) chromosomal translocation was cloned and the fusion protein, PML ± RARa, was identi®ed, and 10 years after these important milestones.
It is now tempting to propose the retinoid maturation-therapy developed for this pathology as a model applicable to any tumor (Hansen et al., 2000) . However, any application of this successful retinoid therapy to other tumor cell types should only be started after taking into account all the speci®cities of the APL cell. Moreover, the particular tissue context in which this pathology develops should also hold our attention. Several speci®c features of the hemopoietic system undoubtedly contribute to the success of retinoid-induced maturation therapy. Hemopoiesis is a developmental process during which cells, at any stage, are subjected to complex humoral and cellular regulations (Dexter et al., 1984; Zipori, 1990; TorokStorb et al., 1999) . Much eort has been devoted to merely trying to understand how retinoid signaling and RARa transcriptional responses are altered in APL. Only rare investigations on the pathophysiology of APL cells have examined the role played by membrane signals on nuclear-receptor functions. The developmental biology literature indicates that combinations of signals play essential roles in the cell speci®city of transcriptional responses. This notion should help to transfer to other tumor-cell types the impressive amount of data gathered over the years on APL, and importantly it should also provide explanations as to why retinoid-induced maturation therapy alone fails.
In this review, we successively, summarize the hemopoietic context in which APL develops, question the relevance of both the biological materials and the methodological approaches used in our investigations. We present data supporting the role for signaling crosstalk in retinoid-induced maturation and cell death, and, ®nally, we diagram the essential membrane receptor-dependent signaling pathways and their cytoplasmic nodes of communication, that`talk' with nuclear-receptor complexes to specify and/or modulate transcriptional responses which determine cell fate.
Setting the stage for leukemic hemopoiesis
First, let us set the stage on which the drama is played: a chromosomal translocation occurs in a cell that has embarked on a fast-developing maturation program.
Hemopoiesis is a developmental process in which a stem cell is progressively modi®ed through distinct short-lived biological programs to give rise to a highly diversi®ed progeny of mature cells. Progenitor renewal, dierentiation, maturation and apoptosis, working in unison, tightly control the size of each cell compartment. These processes are regulated by intrinsic cell features and external in¯uences from the hemopoietic environment (Clark and Keating, 1995; Klein, 1995; Paulson and Bernstein, 1995; Metcalf, 1998; Prosper and Verfaillie, 2001) .
The hemopoietic system is exposed to a number of biological and environmental stresses that cause developmental abnormalities (Testa and Dexter, 1989) , among which, leukemia features one of its most severe pathologies. Leukemias frequently result from mutations and/or chromosomal translocations that aect the expression and/or the function of genes playing regulatory roles in hemopoiesis (Orkin, 1995; Shivdasani and Orkin, 1996; Look, 1997; Introna and Golay, 1999; Crans and Sakamoto, 2001 ). However, not all translocations or mutations result in leukemia; some may have benign consequences or even remain undetected (Brendel and Neubauer, 2000) . The outcome depends, ®rst on the type of genes mutated or involved in the chromosomal translocation and second, on the cell lineage and the developmental stage at which they occur (Rosenfeld and List, 2000) . It is commonly accepted that a hot-spot of alteration is found at a progenitor stage and that genetic mutations impose proliferation of maturation-blocked cells. Therefore, the dierent responses of a lineage cell type to these changes depend on the progenitor cell's developmental history.
The mechanisms by which translocations are generated have not yet been elucidated and, so far, they cannot be produced experimentally, either in vivo, or in vitro. Thus, it remains dicult to determine precisely when, during hemopoiesis, the initial cell defect occurs, and what its immediate consequences are. The only material available for our investigation is the late cell progeny of the cell initially altered by the translocation.
Is the initial t(15;17) cell a physiologically`curable' preleukemic cell? It is extremely dicult to have a precise idea of the developmental history of a leukemia. From the pathophysiology of leukemias (reviewed in Fenaux et al., 1997 Kogan and Bishop, 1999) , the observation that apparently complete remission is compatible with long-term persistence of abnormal bone-marrow (`leukemic') cells (Stone et al., 1988a; Gabert et al., 1989; Khazaie et al., 1994; McCann et al., 1994; Talpaz et al., 1994; Vereecque et al., 2000) and the timing of relapses (Nucifora and Rowley, 1994; Radich, 1999) , it is not unrealistic to think that the translocation event might have occurred several years before the ®rst clinical signs of neoplasia were detected. Once highly sensitive techniques become available to identify them, it cannot be excluded that phenotypically`normal', translocation-bearing cells might even be detected for a very long time in healthy individuals. Figure 1 How could a translocation event modify the fate of a cell interacting with its bone-marrow stromal environment? Either a growth-arrested early progenitor cell settled in a hemopoietic niche or a self-renewing lineage-committed progenitor is altered by the chromosome translocation. This alteration modi®es the normal maturation program and results in several distinct cell responses to environmental signals: [1] the immature cell immediately initiates a continuous proliferation without any cellular or cytokine regulation; [2] the cell's growth is regulated by stromal environment and it is kept`dormant'; [3] the immature cell is deprived of any survival signals and immediately undergoes apoptosis; [4] the cell responds to the inductive hemopoietic environment and matures, even though this maturation is abnormal, and the mature cell dies; [5] the translocation has little eect on the maturation program, the cell responds to the hemopoietic regulators, matures morphologically and functionally, and then dies. These responses occur at physiological levels of retinoid and other regulators; a mixture of these responses are seen at the preleukemic stage Clinically, this means that either: (i) the altered cell is kept`dormant' for years in its stromal environment; (ii) a majority of the altered cells embark along an abortive maturation pathway that leads to apoptotic death of immature preleukemic cells or they are destroyed by the immune system; or (iii) most of its progeny are still capable of maturation and merely escape phenotypical detection. All of these physiological mechanisms could coexist, and even work in concert (Figure 1) .
The hemopoietic microenvironment could well control both early t(15;17) blast cell proliferation and/or induce their (abnormal) maturation. These two responses could occur in vivo at physiological plasma levels of retinoids. Only the rupture of these communications could render physiological retinoid levels insucient for maturation-induction and eventually lead to overt leukemia, detectable within several weeks or months. Therefore, the maturation schemes should integrate the humoral (cytokines, interleukins) and cellular (stromal cells, endothelial cells, phagocytes) and molecular (adhesion molecules, extracellular matrix) microenvironments that generate membrane receptor-mediated signals which undoubtedly cooperate with hormone-dependent (ATRA, VD 3 T 3 ) nuclearreceptor signalings (Figure 2) .
The key to our understanding of a leukemia's pathophysiology has to be found in the combinatorial interactions of signaling pathways along the maturation process and continuing downstream to mature cells apoptosis. Therefore, experimentally restoring the altered environmental signalings should render leukemia cells responsive to physiological levels of retinoids, and vice versa, disrupting membrane receptor-signal transduction or blocking the downstream kinase cascades with inhibitors or antagonists, should install reversible unresponsiveness to pharmacological levels of retinoids. We will see below how exquisitely the biology of NB4 and HL60 cells supports this hypothesis.
How does a t(15;17) cell give rise to a leukemic progeny?
Although most scientists accept that malignancy results from a multistep process (initiation, promotion and progression) (Rosenfeld and List, 2000) , this view is frequently forgotten in the interpretation of experimental data. Indeed, a leukemic cell has a long history passing from a normal state through preleukemia to overt malignancy. We would like to focus on the idea that the leukemic cell population is not the direct result of the translocation (Figure 3) . Two important features emerge. First, leukemia corresponds to a selected subclone (or a mixed population of several subclones) of the initially mutated cell, that exhibits high selfrenewing potential due to secondary alterations that make it unable to mature. The causes of uncontrolled growth and maturation defects can be numerous (desensitization to cytokine signals, constitutive activation of receptors for cytokines, secondary mutations of eector proteins, attenuation or ampli®cation of transcriptional responses) thereby explaining both the diversity of phenotypes and variable responsiveness to pharmacological treatments. Second, clinically detected leukemias, i.e. a bulky ever-expanding leukemia population, may mask preleukemic cells or`dormant' leukemia cells that have conserved various degrees of leukemia`stemness'. An overall appreciation of the tumor in its environment seems essential to be able to trace back to its niche the last leukemia cell, and to envisage its destruction by all available means. Two distinct extracellular contexts, the bone-marrow cellular environment and the extramedullary tissues in which APL cells can grow after marrow egress, have to be considered. Each one furnishes its own signaling arrays.
Details make sense when the general view is sharpened
The role of retinoids in tissue homeostasis was suspected long before speci®c nuclear receptors were characterized (as for 1925, the historical article by Wolbach and Howe, commented in Wolbach and Howe, 1978) . Maturation therapy for APL was also proposed (Breitman et al., 1980) and proved eective in vitro (Breitman et al., 1981) and in vivo (Huang et al., 1988) long before the t(15;17) was characterized molecularly (Borrow et al., 1990; de The et al., 1991) . With some logic, PML ± RARa modi®cation of RARa signal became the sole cause of APL and the key molecular target of retinoids for APL-cell maturation. It is nonetheless disconcerting that the basis of retinoid therapy (Breitman et al., 1980) was unravelled with a non-APL cell, HL60 (Gallagher et al., 1979) , which carries no t(15;17) and thus does not express the chimeric PML ± RARa protein (Dalton et al., 1988) . Since the discovery of variant APL translocations (Chen et al., 1993; Corey et al., 1994; Wells et al., 1996; Arnould et al., 1999) , the complexity of APL biology has increased. That ®ve translocations involving RARa rearrangements with ®ve distinct partner genes (PML, PLZF, NuMA, NPM and Stat-5) generate APL, strongly suggests that RA signaling is the ®rst altered event in any APL (reviewed in Melnick and Licht, 1999) . However, the partner proteins play important roles in the pathophysiology of these variant APL, since the expression of NuMA ± RARa (Wells et al., 1996) and NPM ± RARa (Redner et al., 1997) , like PML ± RARa, are compatible with retinoid-induced maturation, whereas the PLZF ± RARa cells are poorly responsive (Guidez et al., 1994) . The commonly accepted view is that, in APL, PML ± RARa exerts a dominant-negative function on transcription at physiological levels of ATRA, while it works as an agonistactivated receptor under pharmacological retinoid treatment. Therefore, higher nuclear retinoid concentrations are required to induce conformational changes of the PML ± RAR AF-2 domain in order to release corepressors and allow coactivator recruitment, followed by RA-speci®c gene transcription (reviewed in this issue). The conformational changes, the ecacy of binding to corepressors and their release by high ATRA doses count among the key features that characterize APL fusion proteins and the propensity of APL to undergo maturation (Melnick and Licht, 1999; So et al., 2000) .
Despite this important breakthrough in basic research (see articles in this issue), the in cellulo molecular biology of PML ± RARa remains insucient to explain the APL physiopathology, although it explains reasonably well some transcriptional changes, Figure 3 Tumor progression can be caused by stromal cell injuries which disrupt environmental growth-control of a`dormant' preleukemic cell, and induce uncontrolled proliferation of the preleukemic cell (situation [1] in Figure 1 ), and secondary alterations of the preleukemic cell that render it unresponsive to cellular and humoral controls ( Figure 2 ) and abolish both maturation pathways ([4] and [5] in Figure 1 ]. From these events result ®rst a heterogenous population of cells partially, or totally unresponsive to environmental control, then an overt leukemia at least in arti®cial cell-transfection systems. Physiological ATRA signal is one of the triggers that directly activates nuclear receptors and/or induces nuclear receptor expression (Verbeek et al., 2001; Crans and Sakamoto, 2001) . At the same time, membrane receptor-activated signaling pathways converge, activating tissue-, cell type-, or stage-speci®c transcription factors, which together, are necessary to determine cell fate. Therefore, the intracellular context of a cell, at the promyelocytic stage of development, should be obligatory for any investigation applicable to APL pathophysiology. The notion of multiple signaling pathways needed to trigger maturation is reinforced by variable responsiveness of APL variants to ATRA. For instance, the elegant concept, according to which the ATRA-induced conformational change of PML ± RARa is sucient to release corepressors and trigger transcription, unrealistically reduces corepressors to a`static' multiprotein repressor complex. Instead, synergistic signalings (e.g. PKA and Raf/MEK/ERK kinases) likely converge on, and modify both receptors and corepressors, and cooperate with ATRA, leading to the dissociation of the PML ± RARa/corepressor complex. In keeping with this sequence of events, it is likely that cross-talk between membrane and nuclear signals also could remove the PLZF ± RARa blockage of maturation (Jansen and Lowenberg, 2001) .
Better knowledge of the development of APL-like leukemias in transgenic animals, in which tissue-, cell lineage-and stage-speci®c PML ± RARa expressions are precisely controlled, should prove important. The work performed, by Samarut's group on PML ± RARa expression in chicken (Altabef et al., 1996) , then by Bishop's, Pellici's and Pandol®'s groups in transgenic mice (Brown et al., 1997; Grisolano et al., 1997; revealed the extreme developmental complexity of the t(15;17) genetic mutation. In these studies, because of imperfect stage-speci®c promoters, promyelocytes are not the only cells expressing PML ± RARa. Furthermore, while multiple myelopoietic disorders develop, only the late outcome (i.e., overt leukemias), focused researchers' attention. Indeed, the important fact is that leukemias developed in only a minority of transgenic animals and that t(15;17) cells during the long preleukemic stage exhibited variable phenotypes, including some polymorphonuclear granulocyte maturity (see in He et al., 1997) . Does this ®nding mean that, in a physiological context, t(15;17) cells could indeed respond to hemopoietic cytokines and physiological levels of retinoids? Does it mean that, at a preleukemic stage, variable levels of PML ± RARa expression alloẁ hemopoiesis' in a t(15;17) cell? Such questions should be integrated into all of our experimental approaches, in which the level of PML ± RARa expression is tightly controlled.
These questions illustrate the need for an overall understanding of the APL cell physiopathology to better interpret molecular`details', before we can advance mechanistic explanations of retinoid-induced maturation.
Intramedullary cell and humoral signals during APL leukemogenesis

Developmental status of the t(15;17) leukemic promyelocyte
At which stage of myeloid dierentiation the t(15;17) occurs has not yet been de®nitively determined (see in Edwards et al., 1999) . The t(15;17) likely occurred during the dierentiation process of a granulo-monocytic (GM ± CFC) or granulocytic (G ± CFC) progenitor cell. Several features of the maturation stage at which APL blasts are arrested correspond to aǹ abnormal' promyelocyte. In vitro maturation of NB4 cells gives some insights; maturation treatment by VD 3 / TPA indicated that mature cells can exhibit monocytic features (Bhatia et al., 1994; Khanna-Gupta et al., 1994; Testa et al., 1994; Elstner et al., 1997; James et al., 1999) , though ATRA-induced maturation predominently yields a granulocyte type. Once the likely hypothesis of a post GM ± CFC stage alteration is accepted, two important features merit careful attention. First, the promyelocyte maturation environment is mainly intramedullary and marrow egress occurs only later. Second, only 10 cell divisions separate the normal progenitor stage from the normal promyelocyte. After only one or two additional divisions the promyelocyte is converted into post-mitotic neutrophilic granulocytes (Figure 4 ). This scenario suggests that either: (i) the t(15;17) promyelocyte follows the normal maturation program, exactly like normal promyelocytes, and the maturation blockade occurs very close to the growth-arrest point, or (ii) t(15;17) de®nitely modi®es normal granulocytic maturation program, and the t(15;17) blasts express markers that are merely reminiscent or mimicry of the promyelocytic stage. In the latter situation, t(15;17) cells must use for maturation an alternative program or undergo stunted maturation with arrested growth, yielding partly mature granulocytes that ultimately commit to senescence and/or apoptosis. Therapeutically, this distinction may prove important.
Physiological alterations engendered by t(15;17)
The cell on which the PML ± RARa protein exerts its very ®rst biological eects (initiation event) should logically show disturbed RARa-dependent signaling and altered PML function. Since we have no access to this cell, can we evaluate its features from studies on leukemic cells? First, consider PML function: an attractive hypothesis is that PML action in nuclear bodies (NB) is altered. The growth-suppressive action of PML could be precisely altered (Mu et al., 1994 (Mu et al., , 1997 Ahn et al., 1995; ; also see exhaustive reviews on this topic in this issue), at the step immediately preceding myelocyte growth-arrest ( Figure 4) . Second, the crucial question is whether or not PML ± RARa expression aects RARa transcription function so that the expression of some retinoidtargeted genes, key players during granulopoiesis, is directly or indirectly disturbed (see in this issue). The best candidate genes are obviously those involved in progenitor-cell response to hemopoietic signals (Smeland et al., 1994; Ferrero et al., 2001 ; also reviews by Moqattash and Lutton, 1998; Ward et al., 2000) . PML ± RARa can alter transcriptional expression of either cytokines (Dubois et al., 1994a,b; Matikainen et al., 1994 Matikainen et al., , 1996 Chelbi-Alix and Pelicano, 1999) , or their membrane receptors (Hsu et al., 1993; Budel et al., 1993; Hu et al., 1993; Tkatch et al., 1995; Kiyoi et al., 1997; Katayama et al., 1998) , extracellular-signal transducers (Hohmann, 1989; Lee et al., 1999; El Marjou et al., 2000) , cell-cycle regulators (Burger et al., 1994; Liu et al., 1996) , transcription factors and nuclear receptors (Leroy et al., 1991; Chen et al., 1995; Matikainen et al., 1996; Gianni et al., 1997; Matikainen et al., 1997; Morosetti et al., 1997; Pelicano et al., 1997; Ward et al., 2000; Crans and Sakamoto, 2001) or translation regulators (Grolleau et al., 2000) . The t(15;17) blasts might have lost full capacity to respond to humoral factors and the bone marrow inductive hemopoietic environment (see refs. in Nathan and Sporn, 1991; Blalock et al., 1999; McCubrey et al., 2000) , or altered environment no longer ful®ls its regulatory function (Testa and Dexter, 1989; Mayani, 1996) . This survey and a critical review of our ®eld of investigation allows another vision to emerge of what in vivo ATRA therapy for APL could be, and how in vitro leukemia-cell maturation and death should be approached.
Responses of APL-cells to external stimuli: orchestration of signals determines cell fate
In an increasing number of studies, analyses are no longer restricted to the responses of cells to retinoids. Eorts are made to understand the eects of combined treatments. Evidence that multiple signaling pathways modulate or counteract APL cell responses to retinoids has started to accumulate, be recognized and integrated into interpretative process. Lack of space in this review does not allow a detailed analysis of the currently used concepts of signals, signaling pathways and cross-talk. Several essential notions are brie¯y mentioned.
Signals, signaling pathways and cross-talk
Signal transduction merely transmits an information, like an electric wire, but does not intimate the cell to act in any given way. The message is borne inside the cell as an interpretation of the information and depends on the receptor and the molecular context of the cell, i.e.: (i) the cell's biological history, and (ii) the in¯uence of other signals perceived by the cell, sequentially or concomitantly. The intracellular message generated by receptor activation is characterized Figure 4 Leukemic cell responses to maturation therapy and their relationship with lineage and the stage of maturation arrest. The aggressivity and`resistance' to maturation-induction therapy of a leukemia may depend directly on the stage at which the translocation occurs and, the stage of maturation-arrest (these two may be dierent). A leukemia cell with myeloid stem-cell features probably exhibits an extraordinary proliferation potential compared to a t(15;17) promyelocyte. Contrastingly a leukemic promyelocyte is developmentally much closer to the physiological growth-arrest of neutrophils. Note also that, depending on the lineage, the mature cell can be either a very short-lived (neutrophil) or a long-lived cell (monocyte, lymphocyte). Leukemia cells belong to either a highly renewing compartment (a) or a narrow growth-compartment (b); the most favorable therapeutic situation is encountered with t(15;17) promyelocytes that, during ATRA-induced maturation, have only to`cross' from (b) to (c) to enter physiological post-mitotic life, then die naturally by its duration, intensity and the threshold of receptor activation. Similar biological rules also apply to any transducing molecules. The notions of threshold, duration and intensity of signals or messages which are central to neurobiologists and developmental biologists, are dramatically ignored by molecular cell biologists analyzing transcriptional responses to signals and gene expression that produces signaling eectors (receptors and transducing kinases, or e.g., nuclear receptors, coactivators, corepressors). It seems, however, that the experimental era that saw the most crude' and`brutal' uses of uncontrolled ectopic gene expression is over. Cells never speak under torture or the message rings hollow.
The`new-born' intracellular message is an`integration' of all the information received at any time and at any cell site (e.g. membrane, cytoplasm, nucleus). Integration proceeds by combinatorial molecular interactions, which schematically we visualize as the`nodes' of a highly complex network of pathways through which messages are circulating. Two well-documented examples of signal integration`nodes' at the transcriptional level are the multiple signal arrays that converge on the RXR heterodimeric nuclear-receptor complex (Leid et al., 1992) and the CBP/p300 integrator (Blobel, 2000) (Figure 5 ).
The intracellular circuitry is extremely dicult to imagine in full, probably because we are still ignorant of most of its parts. Simply stated, we want visualize it, by analogy, as a computer circuit. In cell biology, it is extremely dicult to test a signal network, since our current biological assays can hardly test more that two or three external signals that vary simultaneously, except if we limit the analysis to the immediate molecular interactions. That cellular responses procede as a cascade of events after hours, days or weeks, gives us an idea of their biological complexity. It is noteworthy that a single external signal can provoke multiple biological responses in the same cell, proliferation, growth-arrest, dierentiation, senescence or apoptosis, depending on what we now call the intracellular context. Responses apparently triggered by a single signal, indeed result from signaling crosstalks.
The chronology of perception of the signals by the cell is important for the formation of the biological message. The complexity of the situation increases when two signals are perceived simultaneously. Positive or negative feedback loops correspond to the situation of retrograde signaling for message ampli®cation attenuation or repression that create the conditions for the cyclic delivery of messages to cell machinery, and alternates refractory and activation periods. This mechanism probably operates during cytoplasmic transduction of messages, but also at the level of the transcription machinery, by cyclic recruitment and release of coactivators and corepressors, or by cyclic expression of dominant-negative (splice-variant) transcription factors. Sassone-Corsi's group made a exquisite and fascinating contribution to this ®eld in the neuro-endocrine system with the attenuation of CREB-mediated PKA and p90 RSK signalings by the inducible cyclic AMP-early repressor ICER (see in De Cesare and Sassone-Corsi, 2000) . This ability to respond dierently, by alternated period of responsiveness and resistance to the same signal (oscillatory responses) likely in¯uences or dictates cell fate in the hemopoietic system, notably the responsiveness to treatments, and could play an important role in the success of therapies based on the action(s) of physiological signals.
Signaling cross-talk and APL-cell maturation
Thanks to HL60 biologists, since the early '80s the notion of cooperation of signaling was rapidely integrated into studies on the biological responses of leukemias to retinoids. All the pertinent data obtained from HL60 investigation, which have paved the way to APL-cell studies, cannot be acknowledged herein. Paradoxically, with the discovery of RARa gene rearrangement by t(15;17) in APL, a dogma, according to which ATRA was`the therapeutical drug', has invaded investigators' imaginations. For many researchers, during almost an entire decade, only the action of ATRA on PML ± RARa, from RARa to PML nuclear bodies has retained attention.
For all those hematologists who carefully examined the morphology of ATRA-treated APL cells or ATRAresponsive NB4 cells, it comes as no surprise that APL cells are not fully responsive to ATRA, even at pharmacological concentrations (some 1000-fold the physiological concentration). The APL blasts still proliferating in ATRA-treated cultures (0.1 ± 1% of the cells) might be ignored or, if detected, may be considered trivial by many biologists. However, for anyone reasoning in terms of a disease state, it is the hallmark of installed`resistance' to treatment, even though the bulk of the population undergoes maturation. As a matter of fact, this is indeed what is observed with the so-called`sensitive' NB4 cell line. Subclones temporarily`unresponsive' or constitutivelỳ resistant' to ATRA ineluctably emerge during treatment. Therefore, considering the clinical and biological features of APL altogether, overt APL should be considered`resistant' to ATRA, albeit with various degrees of unresponsiveness. This view covers all APL translocation variants, including t(11;17).
The hypothesis of mutation selections alone cannot explain the high rate of ATRA-`unresponsive' subclones within a recently cloned population. Adaptation to ATRA treatment (attenuation of response or desensitization to high doses of ATRA) and temporarỳ unresponsiveness' (Duprez et al., 1992) precedes the selection of mutation(s) responsible for resistance, thereby explaining why mutagenesis can accelerate the emergence of resistant clones (Dermime et al., 1993) . We hypothesize that ATRA signal is one of the many pieces of a complex signaling puzzle required for APL maturation ( Figure 5 ). Accordingly, any maturation defect could be`overcome' by the combined action of signalings from either the hemopoietic microenviron-ment, extracellular matrix or agonist activation of membrane receptors mediating intracellular signalings, all acting in concert with hormone nuclear-receptor signalings.
Cross-talk among serine/threonine kinase and steroid nuclear-receptor signalings ATRA ± PKA signaling cross-talk and maturation induction One particularly pertinent maturation-resistant cell, NB4-R1, was found to be fully transcription responsive to RARa agonists, but granulocytic maturation proceded only after agonistic activation of PKA (Ruchaud et al., 1994) . Maturation progressed faster after cyclic AMP triggering when cells were`primed' by ATRA, but simultaneous activation by ATRA and cyclic AMP analogs also induced maturation, thus suggesting that, in NB4-R1, retinoid-signaling requires cyclic AMP to activate secondary eectors which trigger maturation. It is worth noting that, although PML ± RARa was partly degraded in these cells during ATRA treatment,¯uorescence microscopy showed that PML ± NBs remained micro-speckled; cyclic AMP also restored NBs as nuclear macrostructures (Duprez et al., 1996) . In NB4, NB-R1 and NB4 ± R2 cells, cyclic AMP treatment increased PML expression as shown by Western-blotting and increased¯uorescent intensity of the speckled NBs, with no signi®cant change of the PML ± RARa expression in these cells (our unpublished data). This eect is likely independent of PMLgene transcription, and possibly linked to posttranslation PML modi®cation (phosphorylation). Remarkably, as we previously reported (Duprez et al., 1996) , PKA aected ATRA-primed NB4-R1 cells by rapidly increasing of PML ± NB labeling with anti-PML antibody, prior to recovery of normal NBs. Both NB4 and NB4-R1 neutrophils induced to mature by ATRA ± PKA cooperation contained fewer but larger NBs compared to NB4 or HL60 neutrophils induced by ATRA alone (our unpublished data). This observation reinforces the idea that PML and PML ± RARa might be direct targets of PKA. Retinoid-cyclic AMP cross-talk for maturation is not a feature speci®c to APL since it has previously been reported in HL60 and U937 (Olsson et al., 1982) and non-hemopoietic tumor cells (Fontana et al., 1987; Rochette-Egly et al., 1995) . Note that ATRA ± cyclic AMP cross-talk seems to be more complex in HL60, because, in these cells, cyclic AMP signal induces granulocytic maturation independently of ATRA and that ATRA pretreatment partly ablated cyclic AMP-maturation, whereas cyclic AMPanalog pretreatment strongly potentiated ATRA-maturation (Savickiene et al., 1997) .
The stereoisomer Rp-cyclic AMPS functions as a potent cyclic AMP antagonist at the cyclic AMP- binding sites of the PKA regulatory subunits and can block kinase activation (Ruchaud et al., 1994) . PKAdependent phosphorylation is required for ATRA ± cyclic AMP cross-talk and, notably in NB4, a decrease of PKA activity blocks ATRA-induced maturation. This ®nding indicates that a cyclic AMP antagonising a serine/threonine kinase (PKA) creates a condition of unresponsiveness to retinoids. Conversely, sustained PKA signaling allowed near physiological levels of ATRA (3 ± 10 nM) to trigger NB4-cell maturation (Quenech'Du et al., 1998) . A number of membranereceptor agonists, which activate adenylate cyclase, or toxins, which ADP-ribosylate G s proteins, or phosphodiesterase inhibitors reproduce the cyclic AMPanalog eects (Ruchaud et al., 1994) , however, their actions are much weaker than could be expected. The latter could be explained by the well-known desensitization to membrane-receptor signals transduced by GTP proteins and the fact that maturation requires sustained cyclic AMP signaling which must be provided by high concentrations of stable cyclic AMP analogs. This view is in agreement with the ®nding that long-term activation of the agonist-independent Bordetella pertussis adenylate cyclase, engrafted in NB4 cell membrane, is necessary to trigger maturation at physiological retinoid levels (Quenech'Du et al., 1998). Taken together, these data support the notion that the cyclic AMP signal is a major actor in the therapeutic action of pharmacological retinoid levels retinoids in APL.
In keeping with this scenario we hypothesize, on the other hand, that physiological ATRA levels and environmental signals might suce for maturation of t(15;17) blasts, and that defective membrane signaling generating cyclic AMP might be a mechanism by which t(15;17) preleukemic cells progress to overt APL. Studies on the role of physiological ATRA concentrations on APL cells have been neglected. Indeed, we has been observed (e.g., Hsu et al., 1996 , and our unpublished data) that physiological ATRA levels generate an unexpected mitogenic signal in leukemia cells that probably counteracts maturation. This response does not involve PML ± RARa since it occurs in HL60, other myeloid leukemia cell lines and primary cultures of leukemic blasts (our unpublished data). Nonetheless, ATRA growth stimulation depends on a functional RARa and neither HL60-R, nor NB4-R2 cell growth was enhanced.
In the APL-cell context, cyclic AMP pulses are sucient to activate CRE-dependent gene transcription and cyclic AMP-retinoid transcriptional cross-talk occurs. Why adenylate cyclase-coupled membrane receptors seem unable to trigger maturation warrants further studies. It may mean that APL cells require cyclic AMP signaling at multiple steps during maturation. For instance, Garattini's group has shown that cyclic AMP and retinoid cross-talk initiated NB4-cell maturation and, as a secondary event, PKA upregulation cooperates at a transcriptional level to upregulate a RARa (or PML ± RARa) -dependent expression of leukocyte alkaline phosphatase (LAP) (Gianni et al., 1995) . Another hypothesis we, and others, have advanced is that retinoids might be able to deactivate receptor-elicited cyclic AMP-signaling by upstream regulation at the plasma membrane. This possibility is supported by data showing that ATRA suppresses the autonomous maturation response of HL60 to cyclic AMP signaling (Savickiene et al., 1997) .
cyclic AMP generates highly ubiquitous phosphorylation-dependent intracellular signals. Since PKA, a serine/threonine kinase, shares numerous phosphoprotein targets with other serine/threonine-transducing kinases, it cannot at present be excluded that, during ATRA-induced APL-cell maturation, PKA simply mimics other intracellular signals.
PKA, PKC and VD 3 signaling cross-talk Serine/ threonine kinase-dependent pathways cooperate with other nuclear signals to induce leukemic cell maturation. For instance, several reports have shown that PKA or PKC activation could`cross-talk' with either retinoids or VD 3 signaling to orient NB4 or HL60 cell maturation towards neutrophils or monocytes, respectively (Bhatia et al., 1994 (Bhatia et al., , 1996 Ruchaud et al., 1994; James et al., 1999) . These kinases can act by phosphorylation of RXR and RXR-partners (such as TR and VDR, or orphan receptors), and a direct in¯uence (cooperation or competition, facilitation or inhibition) on the type of heterodimer formed, the anity binding of the ligands and the interactions with cofactors.
ATRA partly restored the VD 3 response of NB4 cells. Monocytic maturation operates by antagonizing the inhibitory eect of PML ± RARa (Testa et al., 1994) , possibly via ATRA-induced PML ± RARa degradation. Pertinently, using new VDR-speci®c agonistics and antagonists, Miura et al. (1999) were able to distinguish VDR-dependent from VDR-independent maturation responses, underlining dierences between NB4 and HL60, possibly related to the presence of PML ± RARa in NB4 cells. In an early investigation (Stone et al., 1988b) , bryostatin, a nontumorigenic PKC agonist, was shown to induce monocytic maturation of HL60. In addition to its various therapeutic actions, bryostatin (brie¯y reviewed in Stone, 1997) , cooperates with VD 3 to induce monocyte/macrophage maturation of NB4 cells (Song and Norman, 1999) . The synergistic action of VD 3 and PKC may be due to a VDR-independent mechanism, since VD 3 at least its 6-s-cis locked stereoisomer (nuclear receptor-independent), likely acted through the signal transduction cascade of p42-MAP kinase (ERK 2 ) (Song and Norman, 1999) . Another potential signaling cross-talk for monocytic maturation of NB4 cells activated by 6-s-cis locked VD 3 analogs involved the intracellular calcium pools and calcium-activated proteases (Berry and Meckling-Gill, 1999) . This action of 6-s-cis-VD 3 on maturation could be mediated via calcineurin, a Ca 2+ -calmodulin dependent serine/threonine phosphatase, which seems to be involved in HL60 growth inhibition during VD 3 induced monocytic maturation (Omay et al., 1996) . Note that ATRA could also induce calcineurin-subunit expression during granulocytic maturation (Kihira et al., 1998) .
What emerges from these data is that the interplay of several signaling cross-talks, PKC-VD 3 and PKA ± ATRA, which involve serine-threonine phosphorylation, calcium pathways, as well as the tyrosine kinase cascade, could determine APL-cell fate by directing maturation towards either monocytes/macrophages or neutrophils. Also fascinating is that the choice between maturation programs seems rather¯exible, since maturing cell populations, in the same culture, may have mixed phenotypes, some with monocytic features, others with granulocyte morphology. This indicates that tiny dierences, e.g., environmental milieu or the position in the cell-cycle, at the time cells perceive the inducing signal, may orient cell fate. Two important questions are: does a common signal-pathway trunk exist? and what is the molecular basis for the lineagespeci®c maturation switch. Both could occur simply at a nuclear-receptor level by competition between RARa and VDR for RXR, and/or ligand-independent occupancy by hererodimeric receptors of speci®c hormone-response elements (HRE) in gene promoters. The completion of each maturation program probably requires distinct sets of transcribed genes.
It is also possible that dierences between the maturation responses to PKC ± VD 3 and PKA ± ATRA cross-talks are caused by their opposite eects on the (MAP)ERK pathway. While the non-genomic action of VD 3 analogs activates p42-ERK kinase, PKA can act upstream from ERK via an impaired Ras ± Raf interaction (Marshall, 1995) , and inactivate Raf-1 phosphorylation of its kinase site, which stops the activation of the Raf-MEK-ERK pathway (Hafner et al., 1994) . Accordingly, PKA should have no action on the VD 3 /ERK signaling, which seems to be the case, but paradoxically VD 3 /ERK signaling could well mimic a PKA, CREB-mediated, nuclear response, since CREB-1 is also a substrate of the ERK-activated p90 RSK kinase (see refs in McCubrey et al., 2000) . PKA might have multiple, possibly opposing, actions on NB4 cells: (i) the most obvious eect of PKA activation on ATRA treated NB4-R1 cells is to initiate growth-arrest, then trigger maturation: (ii) other eects could result from action of the PKA on the Ras-Raf-1 pathway, as shown in non-hemopoietic systems (Verheijen et al., 1999; Ciullo et al., 2001) , or from the more common CREB/ATF pathway (De Cesare and Sassone-Corsi, 2000) .
ATRA-Interleukin signaling cross-talk and maturation
Normal granulopoiesis is regulated by ATRA acting on commitment growth and maturation of progenitor cells (Paul et al., 1995; Douer et al., 2000 , see also in this issue). Granulopoiesis also is controlled by bonemarrow stromal cell (endothelial cells, ®broblasts, macrophages) microenvironment producing interleukins (IL1, IL3, GM ± CSF, G-CSF, etc). These regulators control in vitro the survival and the development of GM-and G-CFC into mature cells and are probably playing major roles in determining the fate of t(15;17) preleukemic blasts. CSF treatment of leukemic cells remains dicult because of their antiapoptotic action and their proliferative eect on preleukemic and/or leukemic cells that fail to mature (Truran et al., 1998) . However, combinations of interleukins with dierentiation-inducers have generated clinically exploitable synergistic responses (Stone, 1992; Bollag, 1994) . ATRA and G-CSF synergistically reduce the proliferative potential of normal CD34 + hemopoietic progenitors (Smeland et al., 1994) . ATRA and G-CSF cooperate to induce the eosinophilic maturation of the t(15;17) HT93 APL cell line (Kishi et al., 1998) . G-CSF, but not IL3 or GM ± CSF can enhance the ATRA-induced maturation response of NB4 cells (Hsu et al., 1996) . A strong synergistic interaction between G-CSF and ATRA operates on LAP expression (Gianni et al., 1994) . This speci®c feature of G-CSF on APL cells, not observed on normal cells and other myeloid leukemia, and not observed with other cytokines is intriguing. That ATRA induces G-CSF receptor (Tkatch et al., 1995) and RAR (a/b) (Gianni et al., 1994) transcripts suggests that both a mechanism for the ampli®cation of the maturation signal and durable G-GSF signaling during the maturation of leukemic granulocytes are necessary for cross-talk. Note that, unlike ATRA ± cyclic AMP cross-talk, ATRA-G-CSF cross-talk does not allow the decrease of ATRA levels to obtain maturation. ATRA and its stereoisomer 13-cis RA have been reported to up-regulate distinct interleukin and cytokine transcripts, and thereby generate a complex array of signals. For instance, ATRA up-regulated G-CSF and GM ± CSF receptors (Dubois et al., 1994a, b; Matikainen et al., 1994) , and other cytokines (Hsu et al., 1999) , 13-cis RA up-regulated IL1b mRNA in NB4 and HL60 cells during granulocyte maturation, whereas PMAinduced monocytic maturation of the same cells showed no change of IL1b mRNA. Combined PMA and 13-cis RA action had strong synergistic eects on IL1b expression and granulocytic maturation (Matikainen et al., 1994) . In HL60, ATRA has been shown to upregulate M-CSF (c-fms) receptor (Hsu et al., 1993) . The synergistic induction by M-CSF, VD 3 and TPA of monocytic NB4-cell maturation should also be noted (Bhatia et al., 1994) .
Ras plays an important role in membrane signaling by cytokines; it functions as a relay between G-proteincoupled receptors, ligand-stimulated tyrosine-kinase receptors, cytokine receptors and the MAP-kinase cascade. Altered Ras signaling during preleukemia might disrupt the cross-talk between membrane and nuclear signals, and thereby contribute to tumor progression towards overt leukemia (reviewed in Adams and Cory, 1992; Scheele et al., 2000; Morgan et al., 2001) .
ATRA-Interferon signaling cross-talk and maturation
Another important signaling cross-talk between retinoid and cytokines is featured by the contribution of interferon (IFN) to retinoid-mediated maturation. Gallagher et al. (1987) were the ®rst to report synergistic action of retinoid and IFNa signaling in acute myelogenous leukemia patients. That observation was con®rmed using IFNg on NB4 cells and extended to ATRA-resistant cells (Nason-Burchenal et al., 1996) . The literature in this ®eld has been reviewed (Gaboli et al., 1998; Garattini et al., 1998; Chelbi-Alix and Pelicano, 1999) and is further discussed in this issue. In APL, ATRA induces IFNa synthesis that leads to IFN-mediated Jak-dependent phosphorylation and activation of Stat-1 (Pelicano et al., 1997) ; ATRA also induces IRF-1. In the ATRA-resistant NB4 ± R2 cells ATRA does not up-regulate Stat-1, while IFNg does . ATRA treatment of NB4 cells induces synthesis and secretion of high amounts of IFN (Pelicano et al., 1997 Chelbi-Alix and Pelicano, 1999) and creates a self-sustained loop of membrane-receptor stimulation. Thus, numerous genes have been erroneously named`retinoid-induced genes', whereas they are truly IFN-targeted genes. Therefore, the reported Stat-1 induction by ATRA might be directed by IFN. Stat-1 activated by IFN induces GAS (g-activation site)-promoter dependent transcriptional upregulation of IRF-1; downstream, activated IRF-1 gene expression leads to IRF-2 activation (Matikainen et al., 1996) . Signal cross-talk between ATRA and IFNg (not IFNa or b) partly restores responsiveness to maturation-resistant t(15;17) NB4 cell lines (ChelbiAlix and Pelicano, 1999) .
IFNs regulates the expression of RARs, PML and PML ± RARa Nason-Burchenal et al., 1996) . Indeed, the PML promoter, as well as the promoter of Sp100, another component of PML-NB, contains ISRE (interferon-stimulated response element) and GAS which bind to STATs (Grotzinger et al., 1996; . The antiproliferative action of the IFN ± ATRA combination could be well explained by enhanced expression of PML, which would reinforce the ATRA-dictated growth-arrest. However, the concomitant up-regulation of PML and PML ± RARa by IFN might also have adverse eects on RARa signaling possibly by sequestration of RXR (Chelbi-Alix, personal communication) . Note, that in the event of a mutated PML ± RARa, that exerts a strong dominant-negative action, and in addition, is refractory to ATRA-induced degradation, it could durably compete with the normal RAR allele and reinforce ATRA-resistance. It has been postulated (Lazzarino et al., 1995) that in vivo IFNg treatment could reduce ATRA metabolism, which has been proposed as a cause of`acquired' resistance. On the other hand, the expression of cytochromes P450 (CYPs), is known to be regulated via a number of nuclear receptor ligands (Honkakoski and Negishi, 2000) , including ATRA for CYP26 (White et al., 1997) . In keeping with this idea, recent studies have identi®ed the main human CYPs involved in ATRA metabolism and the principal ATRA metabolites produced (Marill et al., 2000) . Surprisingly, it has been shown that the principal direct ATRA metabolites are (transiently) as active as ATRA at inducing PML ± RARa degradation, normal NB recovery and NB4-cell granulocytic maturation (Idres et al., 2001) . These results weaken the hypothesis of an important role of phase I enzymemediated metabolism in transient ATRA resistance.
Synergistic responses to arsenic-ATRA
Since arsenic trioxide was shown to induce maturation of ATRA-resistant APL cells (Chen et al., 1996) and was eectively used to treat ATRA-resistant APL relapses Shen et al., 1997; Bergstrom et al., 1998) , numerous investigations have been designed to determine its mechanisms of action (MuÈ ller et al., 1998; Shao et al., 1998; Dai et al., 1999; Koken et al., 1999; Sternsdorf et al., 1999; Ohsawa et al., 2000; Kitamura et al., 2000a) . This aspect is exhaustively reviewed by others in this issue. One important feature of the APL-cell response to arsenic is PML ± RARa degradation, by a mechanism that might be partly distinct from ATRA-induced PML ± RARa degradation. Trivalent antimonial salts have also been reported to trigger PML ± RAR degradation (Muller et al., 1998) and maturation of both ATRA sensitive and resistant NB4 cells. Interestingly, ATRA and arsenic trioxide cooperate to induce NB4 cell maturation and apoptosis (Gianni et al., 1998; Lallemand-Breitenbach et al., 1999; Cai et al., 2000; Kitamura et al., 2000b; Jing et al., 2001) . Other combinations with maturation inducers (histone deacetylase-inhibitor (HDACI) trichostatin A, G-CSF) suggest that strong synergistic responses could be exploited for maturation induction (Kosugi et al., 1999; Kitamura et al., 2000a) .
Role of extracellular matrix components, adhesion molecules and retinoids
With rare exceptions, APL develop low extramedullary leukocytosis. This situation may re¯ect that promyelocyte growth and survival require stimulation by the bone-marrow environment or tight interaction of adhesion molecules with extracellular matrix components which retard marrow egress (Allouche and Bikfalvi, 1995; Clark and Keating, 1995; Prosper and Verfaillie, 2001 ). However, it should be noted that APL cells in vitro survive reasonably well for several weeks without stromal cell stimulation, although their proliferation is very slow. Pertinently, the conditions of establishment of the NB4 cell line (Lanotte et al., 1991) indicate that a subpopulation of APL promyelocytes is strongly dependent on stromal cell survival and growth signals. ATRA, G-CSF, IFN and PKA-or PKCtargeted extracellular signals, by enhancing both cytokine production and secretion of competent extracellular matrices and expression of adhesion molecules, directly or indirectly induce APL cell responses by hemopoietic cell environment (MartinThouvenin et al., 1992; Marchetti et al., 1996; Peschel et al., 1996; Hsu et al., 1999) . ATRA also facilitates NB4 cell adhesion and motility on extracellular matrix (Brown et al., 1999; Touhami et al., 1999; Zang et al., 2000, and our unpublished data) and could ease marrow egress. In conjunction with the secretion of growth-stimulatory cytokines, it could contribute to hyperleukocytosis. Activating the CD44-receptor can be exploited to induce myeloid leukemia-cell maturation (Charrad et al., 1999) ; however, the survival potential and the anti-apoptotic signals generated by agonist activation of CD44 could have adverse eects on responses to chemotherapy (Allouche et al., 2000) .
APL cells could ®nd shelters in the marrow environment and could remain`dormant' for long periods of time, unresponsive to both maturation therapy and/or maturation stimuli of cytokines. This could be a major cause of relapse after ATRA therapy. Also, extramedullary tissues into which APL cells could in®ltrate because of ATRA-modi®ed motility (Wiernik et al., 1996; Brown et al., 1999) and the expression of membrane proteases (Ismair et al., 1998) , could constitute sanctuaries (Ko et al., 1999) . On the other hand, ATRA-activated extramedullar environments could produce mitogenic cytokines causing hyperleukocytosis (Vahdat et al., 1994; Ko et al., 1999; Fenaux et al., 2001) .
RAR-independent RXR signaling cross-talk with cyclic AMP induce ATRA-resistant APL-cell maturation
The above-cited literature indicated that several membrane receptor-mediated intracellular signaling pathways cooperate with nuclear signaling by RARa agonistic activation. Notably, these membrane receptor-dependent signals also generated synergistic responses with ligands for other RXR partners (e.g., VDR, TR), but also, strikingly, with several orphan receptor-dependent signals. Since these receptors are not aected by a translocation, they may function at physiological level of agonists, and their synergistic action on ATRA-responses remains partly ignored in vivo or in unde®ned media in vitro. This also indicates that the signal cross-talks important for maturation may have no speci®city for RARs or PML ± RARa and thus no speci®city for APL. Taken together, these data should divert our scienti®c reasoning from the dogma that targeting PML ± RARa by ATRA is the master piece for leukemic promyelocyte maturation.
For several years it has been claimed that`pure' RXR-speci®c ligands,`rexinoids' were devoid of maturation-induction potential on APL. What has been learned from ATRA ± cyclic AMP cross-talk on NB4-R1 cells prompted the determination of whether cyclic AMP signaling cooperates with an autonomous RXR signal, acting independently of the RAR transactivation function. RXR-speci®c ligands, although they can induce a speci®c pattern of gene expression in NB4 cells, induced neither growth-arrest nor maturation of NB4 cells (Benoit et al., 1999) . However, the cross-talk between`rexinoids' and cyclic AMP induced NB4-cell granulocytic maturation and post maturation apoptosis, in both ATRA-responsive NB4 cells and ATRA-resistant NB4-R2 cells mutated in their PML ± RARa ligand-binding domain. This response was ablated by RXR antagonists, but remained unaected by RARa,b,g antagonists. No agonists of other known RXR-partners could disturb this cross-talk. The NB4-R2 PML ± RARa mutation exerts strong dominant-negative repression on RARdependent transcription (Duprez et al., 2000) and excludes any role for RAR in this cross-talk. Unlike maturation responses obtained with ATRA and membrane signaling, PML ± RARa was not degraded and microspeckled NBs were not aected, strongly supporting the conclusion that PML ± RARa played no role in the signaling cross-talk necessary for maturation induction. Independently, therapeutically exploitable RARa-independent RXR-dependent pathways have been reported (Hida et al., 2001) .
Converging signalings control`rexinoid'-induced cell death and maturation
To minimize the role of serum-borne cytokine signals, Benoit et al. (2001) further investigated the eects of rexinoid' in low serum concentration (0.5%). These studies revealed that`rexinoids' are potent inducers of RXR-dependent apoptosis of immature NB4 blast cells. This response occurs in cells resistant to ATRA-maturation (NB4-R2), independently of agonistic activation any known RXR partner, but is abolished by RAR-speci®c agonists or receptor panagonists. cyclic AMP signaling also abolished this apoptotic response. Both RAR agonists and cyclic AMP switch premature cell apoptosis to neutrophil maturation. Importantly, serum factors abolish the RXR-dependent premature cell apoptosis without inducing cell maturation.
Taken together, the above results demonstrate that RAR-(PML ± RARa)-independent, RXR-dependent signaling is a key actor during APL-cell maturation. Its existence has long been ignored because it acts in concert with multiple other membrane-dependent signals to determine cell fate. So far, in the absence of such positive or negative cross-talk, RXR appears to be a nuclear receptor that mediates apoptosis. RXR-speci®c signaling could play a major role in determining cell destiny during development and organogenesis, with tissue-speci®c cooperating signals being progressively generated by the cell microenvironment.
Long-term action of retinoids: telomerase as the ultimate therapeutic target
Telomerase is thought to be involved in cellular replicative life-span extension (Allsopp et al., 2001) and cancer-cell immortalization (Kim et al., 1994) . Telomerase activity is repressed in many somatic tissues, whereas it is activated during tumor progression in most human cancers (Meyerson, 2000) . Telomerase is a ribonucleo-protein complex containing an RNA subunit (hTR) which contains the template for telomeric DNA addition and several protein components, including the catalytic subunit (hTERT) (Feng et al., 1995; Meyerson et al., 1997) and telomerase-associated protein-1 (TP1).
Telomerase is strongly expressed in NB4 cells, and rapid telomerase down-regulation is associated with ATRA-induced maturation (Albanell et al., 1996; Nason-Burchenal et al., 1997) . Using retinoid-responsive NB4 and maturation-resistant NB4-R1, NB4-R2 cells comparatively, Pendino et al. (2001) have identi®ed two distinct pathways for telomerase regulation: the ®rst results in rapid down-regulation of telomerase associated with NB4-cell maturation, which has no real in¯uence on telomere length and cell viability; the second activates a process that develops slowly leading to telomere shortening and death of immature NB4 promyelocytes. Notably, NB4-R1 cells constitutively expressing hTERT are not altered in their ability to mature following cooperative ATRAcyclic AMP stimulation, and show no long-term telomere shortening and no late cell death after ATRA treatment, thus clearly indicating that telomerase activity may in¯uence the outcome of prolonged therapeutic treatments (Pendino et al., 2001) . Taken together, these ®ndings have broader implications, not only on the understanding of biological processes, such as leukemia-cell progression (Kolquist et al., 1998) , immortalization or senescence (Kim et al., 1994) , but also for the design of new therapeutic protocols (Classon and Settleman, 2000) . Telomerase may represent a sensitive target for the treatment of maturation-resistant APL, provided that a functional ATRA-signaling is preserved. Finally, both nuclear receptor-dependent signaling (Misiti et al., 2000; Xu et al., 2000; Nakamura et al., 2001 ) and/or membrane signaling (Kang et al., 1999; Liu, 1999; Breitschopf et al., 2001) cooperate to regulate telomerase.
On our way to a`promising' new APL decade An exhaustive review of the literature on signal crosstalks important for APL-cell maturation is a nearly impossible task. Several interesting cross-talks have not been analysed herein. Computer screening of the data published during the last 20 years provides unsuspected richness (more than 600 papers). The immediate impression is that most of this information remains ignored and unexploited. Quite surprisingly, not so old ®ndings are`rediscovered' and`recooked' with the most recent molecular biology approaches. The second impression is an accumulation of data, sometimes clearly inconsistent, for which no interpretative integration eort has been made. Finally, the immoderate rush to end each scienti®c report with a novel mechanistic explanation, which no investigator can think is not ephemeral, indeed leads to extreme confusion. Unfortunately, these features are not speci®c to this ®eld of research.
After all, the vicissitudes of APL are becoming a monumental saga of something that, 10 year ago, was promised to end shortly. It reminds us what Lewis Thomas (1983) said while listening to the Malher's Symphony no. 9:`Blind alleys and garden paths leading nowhere are the principal hazards in research. Everyone in science knows it, although it is not much talked about, insoluble problems abound.'
